Rituximab for treatment of autoimmune acquired platelet function disorders: description of two cases of acquired Glanzmann thrombasthenia and one case of acquired delta storage pool disease

Br J Haematol. 2019 Dec;187(5):e87-e91. doi: 10.1111/bjh.16243. Epub 2019 Oct 14.
No abstract available

Keywords: Glanzmann thrombasthenia; acquired platelet function disorders; delta storage pool disease; immune-mediated platelet disorder; rituximab.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Albinism / blood
  • Albinism / drug therapy*
  • Autoimmune Diseases / blood
  • Autoimmune Diseases / drug therapy*
  • Female
  • Hemorrhagic Disorders / blood
  • Hemorrhagic Disorders / drug therapy*
  • Hermanski-Pudlak Syndrome / blood
  • Hermanski-Pudlak Syndrome / drug therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Platelet Count
  • Rituximab / therapeutic use*
  • Thrombasthenia / blood
  • Thrombasthenia / drug therapy*

Substances

  • Immunosuppressive Agents
  • Rituximab

Supplementary concepts

  • Albinism with hemorrhagic diathesis and pigmented reticuloendothelial cells